Skip to main content

Table 1 Baseline characteristics of enrolled patients

From: Assessment of Plasmodium falciparum anti-malarial drug resistance markers in pfk13-propeller, pfcrt and pfmdr1 genes in isolates from treatment failure patients in Democratic Republic of Congo, 2018–2019

Characteristics

N

% (95% CI)

p

Age (years)

  

< 0.001

 0–5

172

36.3 (32.0–40.8)

 

 6–14

124

26.2 (22.3–30.4)

 

 15–49

154

32.5 (28.3–36.9)

 

 50–76

24

5.1 (3.3–7.5)

 

Total

474

100.0

 

Sex

  

< 0.001

 Female

272

57.4 (52.8–61.9)

 

 Male

202

42.6 (38.1–47.2)

 

Total

474

100.0

 

Anti-malarial used for initial episode

  

0.009

 ASAQ

196

41.4 (36.9–45.9)

 

 AL

273

57.6 (53.0–62.1)

 

 DP

5

1.1 (0.3–2.4)

 

Total

474

100.0

 

Enrolled patients per site

  

< 0.001

 Bolenge

88

18.6 (15.2–22.4)

 

 Fungurume

83

17.5 (14.2–21.2)

 

 Kabondo

20

4.2 (2.6–6.4)

 

 Katana

143

30.2 (26.1–34.5)

 

 Kingasani

113

23.8 (20.1–27.9)

 

 Vanga

27

5.7 (3.8–8.2)

 

Total

474

100.0

 

Detection of P. falciparum by PCR

  

< 0.001

 Negative

110

23.2 (19.5–27.3)

 

 Positive

364

76.8 (72.7–80.5)

 

Total

474

100.0

 
  1. AL artemether-lumefantrine, ASAQ artesunate-amodiaquine, DP dihydroartemisinin-piperaquine, N number